In Cox proportional hazards regression analyses (Table 2), compared with KRAS‐wild‐type tumors, KRAS c.34G>T (p.G12C)‐mutated tumors were associated with a higher 5‐year colorectal cancer‐specific mortality (with univariable HR, 1.97; 95% confidence interval [CI], 1.13–3.42; p = 0.017; and multivariable HR, 1.82; 95% CI, 1.05–3.17; p = 0.035). This evidence concerns the gene KRAS and colorectal cancer.